Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Travere Therapeutics Inc is a biotechnology business based in the US. Travere Therapeutics shares (TVTX) are listed on the NASDAQ and all prices are listed in US Dollars. Travere Therapeutics employs 262 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$25.23|
|52-week range||$12.75 - $33.09|
|50-day moving average||$23.80|
|200-day moving average||$19.62|
|Wall St. target price||$32.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.33|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||2.98%|
|1 month (2021-09-23)||0.80%|
|3 months (2021-07-23)||90.70%|
|6 months (2021-04-23)||4.52%|
|1 year (2020-10-23)||20.43%|
|2 years (2019-10-23)||122.88%|
|3 years (2018-10-23)||25.43|
|5 years (2016-10-21)||22.59%|
|Revenue TTM||$204.1 million|
|Gross profit TTM||$192.2 million|
|Return on assets TTM||-9.85%|
|Return on equity TTM||-72.83%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
There are currently 6.5 million Travere Therapeutics shares held short by investors – that's known as Travere Therapeutics's "short interest". This figure is 5.5% down from 6.9 million last month.
There are a few different ways that this level of interest in shorting Travere Therapeutics shares can be evaluated.
Travere Therapeutics's "short interest ratio" (SIR) is the quantity of Travere Therapeutics shares currently shorted divided by the average quantity of Travere Therapeutics shares traded daily (recently around 818733.83458647). Travere Therapeutics's SIR currently stands at 7.98. In other words for every 100,000 Travere Therapeutics shares traded daily on the market, roughly 7980 shares are currently held short.
However Travere Therapeutics's short interest can also be evaluated against the total number of Travere Therapeutics shares, or, against the total number of tradable Travere Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Travere Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Travere Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.1554% of the tradable shares (for every 100,000 tradable Travere Therapeutics shares, roughly 155 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Travere Therapeutics.
Find out more about how you can short Travere Therapeutics stock.
We're not expecting Travere Therapeutics to pay a dividend over the next 12 months.
Travere Therapeutics's shares were split on a 1:9 basis on 7 November 2011. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Travere Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Travere Therapeutics shares which in turn could have impacted Travere Therapeutics's share price.
Over the last 12 months, Travere Therapeutics's shares have ranged in value from as little as $12.75 up to $33.0899. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Travere Therapeutics's is 0.7132. This would suggest that Travere Therapeutics's shares are less volatile than average (for this exchange).
Travere Therapeutics, Inc. , a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.